Evidence map›Paper›PMID 38987741›Full record

ArticleMicrobial cell factories2024

Optimization of biotransformation processes of Camarosporium laburnicola to improve production yields of potent telomerase activators.

Melis Küçüksolak, Hasan Buğra Çoban, Erdal Bedir

Abstract read
In one paragraph

Article in Microbial cell factories, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Melis KüçüksolakDepartment of Bioengineering, Faculty of Engineering, İzmir Institute of Technology, Urla, İzmir, 35433, Turkey.
Hasan Buğra Çobanİzmir International Biomedicine and Genome Institute, Dokuz Eylül University, Balçova, İzmir, 35340, Turkey.
Erdal BedirDepartment of Bioengineering, Faculty of Engineering, İzmir Institute of Technology, Urla, İzmir, 35433, Turkey. erdalbedir@iyte.edu.tr.

Funding

İzmir Yüksek Teknoloji Enstitüsü 2017İYTE63Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 119Z870
6 · The paper itself

Abstract

backgroundTelomerase activators are promising agents for the healthy aging process and the treatment/prevention of short telomere-related and age-related diseases. The discovery of new telomerase activators and later optimizing their activities through chemical and biological transformations are crucial for the pharmaceutical sector. In our previous studies, several potent telomerase activators were discovered via fungal biotransformation, which in turn necessitated optimization of their production. It is practical to improve the production processes by implementing the design of experiment (DoE) strategy, leading to increased yield and productivity. In this study, we focused on optimizing biotransformation conditions utilizing Camarosporium laburnicola, a recently discovered filamentous fungus, to afford the target telomerase activators (E-CG-01, E-AG-01, and E-AG-02).

resultsDoE approaches were used to optimize the microbial biotransformation processes of C. laburnicola. Nine parameters were screened by Plackett-Burman Design, and three significant parameters (biotransformation time, temperature, shaking speed) were optimized using Central Composite Design. After conducting validation experiments, we were able to further enhance the production yield of target metabolites through scale-up studies in shake flasks (55.3-fold for E-AG-01, 13-fold for E-AG-02, and 1.96-fold for E-CG-01).

conclusionFollowing a process optimization study using C. laburnicola, a significant increase was achieved in the production yields. Thus, the present study demonstrates a promising methodology to increase the production yield of potent telomerase activators. Furthermore, C. laburnicola is identified as a potential biocatalyst for further industrial utilization.

Indexed as

BiotransformationTelomeraseEnzyme ActivatorsEnzyme ActivatorsTelomeraseAnti-agingEndophytic fungiProcess optimizationTelomerase activatorWhole-cell biotransformation

Identifiers

PMID38987741
PMCPMC11234680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.